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BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It
has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced
oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional
capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions.
METHODS: Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3mgkg
 1
weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick
end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial
malondialdehyde and 4-hydroxynonenal immunodetection.
RESULTS: Dexrazoxane (60mgkg
 1) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction,
profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it
has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and
effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters
significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in
anthracycline-induced lipoperoxidation.
CONCLUSION: This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic
anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action
of DEX.
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Anthracycline antibiotics (ANT, e.g., doxorubicin, daunorubicin
(DAU) or epirubicin) rank among the most potent and clinically
important anticancer drugs ever developed. However, their clinical
utility is markedly hampered by a significant risk of cardiotoxicity,
especially that of a chronic and delayed type (Jones et al, 2006).
The current conceptual model proposes that each anthracycline
dose (cycle) induces an amount of damage to the myocardium.
This injury, however, may stay clinically silent as long as the
cumulative damage to cardiomyocytes does not exceed a certain
functional reserve of the myocardium (Ewer and Benjamin, 2006).
With an increasing cumulative dose, alterations to myocyte
ultrastructure may progress further towards end-stage degenera-
tion and cell death (Billingham et al, 1978; Von Hoff et al, 1979).
The ANT cardiomyopathy that develops in this manner manifests
itself in severe heart failure with poor overall prognosis (Jones
et al, 2006; Gianni et al, 2008).
Anthracycline cardiotoxicity has been traditionally associated
with oxidative stress-induced injury with a catalytic involvement of
free cellular iron (Keizer et al, 1990). For many years, it has been
believed that reactive oxygen species (ROS)-induced degenerative
changes and subsequent non-programmed cell death of the
cardiomyocytes are the primary (or even exclusive) hallmarks of
ANT cardiomyopathy (Billingham et al, 1978; Godfraind, 1984;
Lewis and Silver, 2001). However, with the wider appreciation of
the function of programmed cell death in cardiac diseases, this
view is undergoing considerable change. More recently, several
experimental in vitro as well as in vivo reports have suggested that
the exposure of cardiomyocytes to ANTs also triggers a
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swell-orchestrated apoptotic mode of cell death (Sawyer et al, 1999;
Arola et al, 2000; Nakamura et al, 2000; Yamaoka et al, 2000;
Kotamraju et al, 2004; Konorev et al, 2008).
Dexrazoxane (DEX, ICRF-187) is the only well-established and
clinically approved cardioprotectant against ANT cardiotoxicity
(Wouters et al, 2005). The DEX is traditionally characterised as a
prodrug, which is activated inside cardiomyocytes to the metal-
chelating metabolite ADR-925. The latter active form of the drug is
proposed to prevent ANT-induced and ROS-mediated cellular
degeneration and non-programmed death of cardiomyocytes (Van
Vleet et al, 1980; Herman et al, 1981). However, an in vitro study
using isolated cardiomyocytes suggested that, in clinically
relevant concentrations of ANTs, DEX may instead work
through the prevention of programmed (apoptotic) cell death
(Sawyer et al, 1999).
Hence, the main aim of this study was to examine whether DEX-
afforded cardioprotection against chronic ANT cardiotoxicity
in vivo involves a rescue of cardiomyocytes from apoptosis. In
addition, the effects of DEX on the main apoptotic pathways and
relations to lipoperoxidation were investigated.
MATERIALS AND METHODS
Animals and study design
This study was conducted using the previously well-established
and accepted model of chronic ANT cardiotoxicity in rabbits
(Gersl and Hrdina, 1994; Simunek et al, 2004; Sterba et al, 2006).
Chinchilla male rabbits (3.48±0.03kg) were randomised into three
groups receiving (1) saline (1mlkg
 1, i.v., n¼8; Natrium
Chloratum, Biotika, Slovenska ´, L’upc ˇa, Slovakia); (2) DAU
(3mgkg
 1, i.v., n¼11; Daunoblastina; Pharmacia Italia, Nerviano,
Italy); and (3) DEX (60mgkg
 1, i.p., n¼8; Cardioxane, Novartis,
Basel, Switzerland) 30min before each DAU administration
(DEXþDAU group). All the substances were administered once
weekly for 10 weeks. Administration of drugs, blood sampling and
non-invasive measurements during the study were carried out
under combined anaesthesia – ketamine (50mgkg
 1, i.m.;
Narketan, Ve ´toquinol AG, Ittigen, Switzerland) and midazolam
(1.25mgkg
 1, i.m.; Midazolam Torrex, Torrex Chiesi Pharma,
Vienna, Austria). Pentobarbital (30mgkg
 1, i.v.; Sigma-Aldrich,
Prague, Czech Republic) was used for anaesthesia during final
invasive haemodynamic measurements and for an overdose of
animals at the end of the experiment.
The study was terminated 5–7 days after the last drug
administration. During the subsequent autopsy, hearts were
rapidly excised, washed and briefly perfused with ice-cold saline.
Heart ventricles were transversely cut under the atrio-ventricular
septum and a block of left ventricular (LV) tissue was used for
histological examination. The rest of the LV free wall was snap-
frozen and homogenised under liquid nitrogen and kept frozen at
 801C for further analysis.
All experiments were approved and supervised by the Ethical
Committee of Charles University in Prague, the Faculty of
Medicine in Hradec Kra ´love ´, and were in accordance with the
Institute of Laboratory Animal Resources (1996).
Cardiac function measurements
During the time course of the experiment, LV systolic function was
followed by echocardiography (Vivid 4, with a 10MHz probe; GE
Medical Systems Ultrasound; GE Healthcare, Chalfont, St Giles,
UK). The LV fractional shortening (FS) was obtained from LV end-
systolic and end-diastolic diameters determined by guided M-
mode scanning from the left parasternal long axis view.
At the end of the study, an invasive examination of LV
contractility was carried out using a Micro-Tip pressure catheter
(2.3F, Millar Instruments, Houston, TX, USA) connected to a data
acquisition system (Powerlab, ADInstruments Pty., Castle Hill,
Australia). The Chart 5.4.2 software (ADInstruments Pty.) was
used for data analysis and calculation of the first derivative
of the LV pressure rise in the isovolumic phase of systole
(index dP/dtmax).
Cardiac troponin determination
Plasma concentrations of cardiac troponins T and I were
determined using an Elecsys Troponin T STAT Immunoassay
(Roche Diagnostics, Basel, Switzerland) and an ADV AxSYM
troponin I Immunoassay (Abbott Laboratories, East Windsor, NJ,
USA).
Histology and TUNEL labelling
Tissue blocks (B3mm thick) of the transversely sectioned LVs
were fixed by immersion in 4% neutral formaldehyde for 3 days.
Thereafter, they were embedded in paraffin and numbered serial
sections (6mm thick) were cut. The first two sections in each set
were stained with H&E and Masson’s blue trichrome for
morphological evaluation, whereas the third, sixth and ninth
sections were used for a terminal deoxynucleotidyl transferase
biotin-dUTP nick end labelling (TUNEL) assay using an In situ
Cell Death Detection Kit AP (Roche Diagnostics), according to the
manufacturer’s recommendation. The representative photomicro-
graphs were obtained with a MicroImage software version 4.51
(Media Cybernetics, Laboratory Imaging, Prague, Czech Republic).
Quantification of TUNEL-positive nuclei
Three serial LV sections were taken from each heart (representing
a distance of 42mm) and labelled with the TUNEL assay.
Photomicrographs of the tissue ( 200 magnification) were made
in numbered series using an Olympus (Central Valley, PA, USA)
AX 70 microscope equipped with a digital camera Pixelink
PL-A642 (Vitana Corp., Ottawa, Ontario, Canada). Quantitative
analysis was performed by NIS image-analysis software (Labora-
tory Imaging) using 20 randomly chosen fields that represented
approximately 3.7mm
2 of the LV area on a given section. The
selection of fields was based on the generation of random numbers
by SigmaStat software (SPSS Inc., Chicago, IL, USA). Only the
appropriately stained nuclei of the cardiomyocytes at the section
level were carefully counted. The average number of TUNEL-
positive nuclei per square millimetre of the LV tissue was
determined.
Caspases activity determination
The activities of individual caspases were determined in the LV
myocardium using commercially available kits. Myocardial
samples were homogenised in a Lysis Buffer (BioVision, Mountain
View, CA, USA) on ice. After centrifugation, the supernatants were
collected for a further analysis of caspase activity. Caspase 12
activity was determined using a Caspase-12 Fluorometric Assay Kit
(BioVision), whereas the activities of caspase 3/7, 8 and 9 were
determined using luminescence Caspase-Glo Assays (Promega,
Madison, WI, USA) according to the manufacturer’s instruction.
The fluorescence and luminescence units were normalised on the
protein content in each sample. The fold-increase in caspase
activity was determined by a comparison of these results, with the
levels determined in the samples obtained from control animals.
Myocardial lipoperoxidation analyses
For a reliable analytical determination of malondialdehyde (MDA)
in myocardial samples, a thiobarbituric acid-independent HPLC
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smethod was used. This method has been appropriately validated
with respect to selectivity, precision, accuracy and linearity
following standards of FDA Guidelines for Bioanalytical Method
Validation (FDA Guidance Document 2001). Radioimmunopreci-
pitation assay buffer (500ml) was added to the LV samples
(B70mg of tissue) and the mixture was homogenised and
vortexed. After centrifugation, the supernatant was withdrawn
and analysed according to Pilz et al (2000). Briefly, 50ml of NaOH
(6moll
 1) was added, and after vortexing, the solution was kept at
601C for 30min. The samples were then cooled on ice and 125mlo f
perchloric acid (35% (v/v)) was added. After centrifugation, 250ml
of supernatant was taken and derivatisation was performed using
25ml of 5mmoll
 1 2,4-dinitrophenylhydrazine. After 10min in the
dark, the solution was analysed using an HPLC system (Shimadzu,
Kyoto, Japan).
In addition, the immunohistochemical detection of 4-hydro-
xynonenal (4-HNE) was used as a complementary approach to
myocardial lipoperoxidation assessment on transverse sections of
the LV myocardium (two per animal). Incubation with a
monoclonal 4-HNE antibody (Oxis International Inc., Beverly
Hills, CA, USA; dilution 1:40) was performed overnight at 41C.
Secondary biotinylated donkey anti-mouse antibody (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA, USA;
dilution 1:500) was applied for 40min at room temperature. For
visualisation 3,30-diaminobenzidine-tetrahydrochloride (Sigma-Al-
drich) was used. Sections were counterstained with Gill’s
haematoxylin.
Protein concentration determination
Protein concentrations in the analysed samples were determined
using a BCA Assay Kit according to the manufacturer’s protocol
(Sigma-Aldrich).
Data analysis
The statistical softwares, SigmaStat 3.5 (SPSS Inc.) and STATIS-
TICA Cz (StatSoft, Tulsa, OK, USA), were used in this study. All
data are expressed as mean±s.e.m. Statistical significance was
determined using one-way ANOVA unpaired test or paired t-test.
Correlation analyses were performed using Spearman’s method
and regression analysis. Two independent exploratory multivariate
statistical methods (Hierarchical Tree Clustering and Principal
Component Analysis) were used to identify the natural groupings
of individual animals in this study with respect to the following
evaluated parameters – LV cardiac function parameters, cardiac
troponins and markers of apoptosis and lipoperoxidation (com-
prising a total of 10 variables).
RESULTS
General toxicity
The general appearance and mortality of animals were recorded
during the time course of the study. In the control group, no
premature mortality was observed and body weights were
significantly increased during the experiment as compared with
the initial values (3.50±0.03 vs 4.64±0.13kg; Po0.01). On the
other hand, DAU treatment resulted in premature death in two out
of eleven animals (18%) and no change in body weight was
observed in this group (3.45±0.07 and 3.47±0.23kg, beginning vs
end; NS). Furthermore, in prematurely dead animals, a necropsy
examination revealed marked signs of blood congestion involving
massive hydrothorax (B60ml) in both animals, in addition to
ascites (25 and 35ml). In addition, in comparison with the control
group, the heart-to-body-weight ratio was found to be significantly
increased in this group (2.82±0.18 vs 2.15±0.10gkg
 1, respec-
tively, Po0.05).
In contrast to the DAU group, all DEX co-treated animals
survived until the end of the study and their well-being was
evidenced by a significant body weight increase during the
experiment (3.50±0.07 and 3.99±0.07kg, beginning vs end;
Po0.01). No hydrothorax or ascites were found in this group
and also the heart-to-body-weight ratio (2.55±0.13gkg
 1) showed
no significant difference compared with that in the control group.
Left ventricular systolic function
Echocardiographically determined FS revealed a progressive and
significant decline in LV systolic function in DAU-treated animals,
starting by the eighth week (Figure 1A). In addition, an impaired
LV systolic performance was also found in this group by invasive
contractility examination performed at the end of the study
(Figure 1B). In contrast, animals receiving DEX before each DAU
injection showed nearly the same systolic function as the controls,
which was evident from the outcomes of both types of the LV
systolic examination (Figure 1A and B).
Plasma concentrations of cardiac troponins
Repeated administration of DAU led to significant elevations of
plasma levels of troponins T and I. Correspondingly, DEX-afforded
cardioprotection was associated with significantly lower plasma
levels of both cardiac biomarkers (Figure 2A and B).
Histological examination
A light microscopy examination of the LV myocardium of rabbits
receiving DAU revealed profound focal toxic damage (Figure 3B).
These changes comprised cellular degeneration with a mild-to-
prominent loss of myofibrils and cytoplasmic vacuolisation. The
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Figure 1 (A) Echocardiographically determined left ventricular (LV)
fractional shortening (FS) during the time course of experiment. (B)
Invasively determined index of LV contractility (index dP/dtmax) at the end
of the experiment. Statistical significance in comparison with ‘*’ the initial
values within each group (paired t-test, Po0.05), ‘c’ control, ‘d’
daunorubicin and ‘x’ DEXþDAU groups (ANOVA, Po0.05).
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sadvanced degenerative changes resulted in cell death of the non-
programmed type. The affected cardiomyocytes were observed to
undergo cellular swelling and gradual disintegration. Furthermore,
whenever the dead cells formed larger foci, their remnants were
replaced by a subsequent proliferation of fibrotic tissue that
resulted in interstitial fibrosis. In sharp contrast, an examination
of samples obtained from both the control and the DEXþDAU
groups revealed a comparable morphological picture, with only
subtle differences observed (Figure 3A and C). Importantly, the
degenerative changes resulting in cell death, conspicuous in the
DAU group, were rarely seen in the DEXþDAU group.
TUNEL labelling and quantification of TUNEL-positive
nuclei
Examination of the TUNEL-labelled LV tissue sections showed only
few positive cells in the investigated areas within the control group
(Figure 4A). However, nuclear TUNEL positivity was significantly
increased in the myocardium of DAU-treated animals (Figure 4B and
D). The majority of TUNEL-positive nuclei were found in the
cardiomyocytes that lacked any signs of typical degenerative changes,
or these changes were present in their initial stages only. Unlike
degenerative changes, TUNEL positivity did not show any regular
pattern of appearance in the LV myocardium.
In the DEXþDAU group, the number of TUNEL-positive nuclei
significantly declined to nearly the same values as determined in
the control animals (Figure 4C). TUNEL-positive nuclei were
found only in scattered isolated cells without any specific pattern.
In addition, in individual animals, this parameter showed a
significant correlation with LV systolic function (Figure 4E).
Caspase activity
Determination of the activity of all major caspases associated with
apoptotic signalling showed triggering of multiple apoptotic
pathways in the LV myocardium of DAU-treated animals. As seen
in Figure 5A, chronic ANT treatment resulted in a significant
increase in the activity of the executive downstream caspases 3 and
7, in comparison with that in the control group. In addition, the
activities of caspases 8, 9 and 12 were also found to be increased in
the DAU group (Figure 5B–D). In the DEX co-treated animals, the
activity of the executive caspases 3/7 was significantly lower than
that in the DAU-alone group (Figure 5A). Furthermore, activation
of all major upstream pathways (i.e., caspases 8, 9 and 12) was
effectively prevented by DEX co-treatment. There were no
significant differences in the activities of individual caspases
between the control and the DEXþDAU group (Figure 5B–D).
Interestingly, the activities of these caspases showed a significant
and strong correlation with LV systolic function (Figure 6A–D).
Myocardial lipoperoxidation analyses
Using a selective HPLC method, significantly increased levels of
total MDA(a widely used marker of lipoperoxidation) were
determined in the LV myocardium of DAU-treated animals
(Figure 7A). Surprisingly, DEX co-administration was not
associated with a significant decrease in MDA levels. The MDA
levels in the DEXþDAU group remained significantly higher than
those in the controls and were close to the levels determined in the
DAU-alone group. Furthermore, the MDA levels showed only a
poor correlation with caspase 3 activity (Figure 7B) and no
significant correlation with the activities of caspases 8 and 9
(Figure 7C and D). Interestingly, no association was also found
between myocardial MDA levels and LV systolic function
(Figure 7F).
The immunohistochemical detection of 4-HNE (another in-
dependent marker of lipoperoxidation) in the LV myocardium
revealed a markedly higher response in the samples obtained from
DAU-treated animals than in corresponding controls (Figure 8A
Figure 3 (A–C) Histological examination of the left ventricular (LV) myocardium. Masson’s blue trichrome; bar¼20mm. In the control group (A),
normal structure of the myocardium was observed. In the DAU group (B), foci of cardiomyocytes showing profound degeneration (asterisks) were found.
Marked morphological changes comprise cytoplasmic vacuolisation, cell swelling and loss of myofibrils resulting in cell death with subsequent development of
interstitial fibrosis (arrow). The LV myocardium of DEX co-treated animals (C) showed largely preserved normal morphology with only subtle changes; signs
of cardiomyocyte degeneration were scarce (asterisk).
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(B) troponin I (cTnI) in individual animals at the end of the experiment.
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sand B). The 4-HNE signal was predominantly detected within the
cardiomyocytes, whereas interstitial cells showed poor immunor-
eactivity. The myocardium of DEX co-treated animals (Figure 8C)
showed a 4-HNE signal intensity that was largely comparable with
that in the DAU-alone group. Although in some cases a moderate
degree of reduction of the 4-HNE signal could be found in the
DEXþDAU group, it was clearly always very far from being
complete. No distinct changes in 4-HNE signal localisation could
be found between the DAU and DEXþDAU groups.
Exploratory data analysis
Hierarchical Tree Clustering (Figure 9A) and Principal Component
Analysis (Figure 9B) were used to identify natural groupings
within the 27 individual animals in this study with respect to the
index of their LV functions (FS and dP/dtmax), the plasma levels of
cardiac troponins T and I, markers of apoptosis (TUNEL positivity
and activities of caspases) and lipoperoxidation. Both exploratory
data analysis approaches independently resulted in the grouping of
all examined animals into two well-separated clusters. In the first
cluster (I), all animals from the control and the DEXþDAU
groups were found, whereas the individuals from the DAU group
were arranged into a second cluster (II). Almost all animals from
the DAU group appeared in one cluster, with the exception of two
animals (prematurely dead) associated with the most profound
changes. In addition, this exploratory data analysis identified
caspase activities as the parameters with the highest impact on the
natural grouping of animals.
DISCUSSION
In this study, repeated chronic DAU administration resulted in
increased mortality, which was accompanied by severe blood
congestion and heart failure. Echocardiographically determined FS
revealed a progressive decline in LV systolic function, and this was
further supported by an independent LV catheterisation examina-
tion performed at the end of the experiment. Dexrazoxane (ICRF-
187), administered before each DAU injection, was capable of fully
protecting the animals from both premature death and LV
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Figure 4 Terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling (TUNEL) assay. (A–C) Representative samples of left ventricular (LV)
myocardium labelled with TUNEL in the control (A), DAU (B) and DEXþDAU (C) groups. The arrows indicate examples of TUNEL-positive nuclei;
bar¼20mm. (D) Quantitative analysis of TUNEL assay. Statistical significance (ANOVA, Po0.05) in comparison with ‘d’ daunorubicin group. (E) Scatterplot
of the LV fractional shortening vs number of TUNEL-positive nuclei per square millimetre and results of the Spearman’s correlation analyses.
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sdysfunction. These findings illustrate the excellent cardioprotec-
tive potential of DEX, and the overall result is well in line with the
outcomes of preclinical studies and clinical trials (Cvetkovic and
Scott, 2005).
Histological examination of the LV myocardium in the DAU-
treated animals revealed profound focal damage. These advanced
degenerative changes (mainly cytoplasmic vacuolisation and loss
of myofibrils) evidently resulted in non-programmed cell death.
Such cardiomyocytes showed cellular swelling and a gradual
disintegration. Importantly, DEX afforded very effective cardio-
protection against these degenerative changes in a degree evidently
comparable with previously published reports using morpho-
metric quantitation (Herman et al, 1981, 1985, 1994). At the same
time, the plasma levels of both cardiac troponins T and I were
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Figure 6 (A–D) Scatterplots of the cardiac function (LV fractional shortening (FS)) vs activity of individual caspases as determined by Spearman’s
correlation analyses: caspases 3/7 (A), caspase 8 (B), caspase 9 (C) and caspase 12 (D). LU, luminescence units; FU, fluorescence units.
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sfound to be markedly increased. The troponin concentrations
found in this study were indeed lower than those associated with
acute ischemia–reperfusion injury or isoproterenol cardiotoxicity
(Bertinchant et al, 2000). However, it should be taken into account
that chronic anthracycline cardiotoxicity progresses very slowly
(several weeks) and is typically of a focal nature. Although the
precise mechanism of troponin release into the blood stream has
not yet been revealed, traditionally it is linked to necrotic death of
cardiomyocytes, when the integrity of the cytoplasmic membrane
is compromised (Horenstein et al, 2000; Wallace et al, 2004;
Arbustini et al, 2008). Hence, DEX administration provided nearly
a full protection of myocytes from the above-described advanced
degenerative changes, as well as from the rise of cardiac troponin
plasma levels. Specifically, the above-stated processes suggest a
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Figure 7 (A) Total malondialdehyde (MDA, marker of lipoperoxidation) levels in LV myocardium. Statistical significances (ANOVA, Po0.05) in
comparison with ‘c’ control group. (B–E) Scatterplots of MDA levels in the left ventricular myocardium vs activity of individual caspases and results of the
Spearman’s correlation analyses: caspases 3/7 (B), caspase 8 (C), caspase 9 (D) and caspase 12 (E). (F) Scatterplot of myocardial MDA levels vs LV
fractional shortening (FS) and results of the Spearman’s correlation analyses. LU, luminescence units; FU, fluorescence units.
Figure 8 Representative samples of left ventricular (LV) myocardium showing 4-hydroxynonenal staining in the control (A), DAU (B) and DEXþDAU
(C) groups.
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srescue of cardiomyocytes from non-programmed cell death, which
likely triggers the process of cardiac remodelling. These findings
correspond well with the widely accepted concept of DEX-afforded
cardioprotection (Van Vleet et al, 1980; Herman et al, 1981).
In addition to the ‘traditional’ pathway of ANT-induced and
ROS-mediated cardiomyocyte degeneration possibly resulting in
non-programmed cell death, several lines of evidence have shown
that apoptotic cell death may also be involved in anthracycline
cardiotoxicity (Sawyer et al, 1999; Arola et al, 2000; Nakamura
et al, 2000; Yamaoka et al, 2000). This is in contrast to very early
reports (Zhang et al, 1996). In good agreement with numerous
recent reports, we have shown that chronic ANT treatment leads to
a significant increase in the number of TUNEL-positive nuclei in
the LV myocardium, along with an increased activity of the
executive downstream caspases 3 and 7. Interestingly, both these
parameters corresponded well with the LV systolic function in
individual animals. Previous studies have suggested in the main
that either the intrinsic (i.e., mitochondrial, caspase 9 dependent)
(Childs et al, 2002) or extrinsic (receptor mediated, caspase
8dependent) (Nakamura et al, 2000) pathways are pivotal in the
ANT-induced triggering of cardiomyocyte apoptosis. Our investi-
gation showed the activation of both caspases 8 and 9, thereby
suggesting a concomitant involvement of both previously reported
pathways and/or a cross talk between them. In addition, we have
shown for the first time that the recently described endoplasmic/
sarcoplasmic reticulum (ER/SR) pathway (caspase 12-mediated)
might also contribute to chronic ANT cardiotoxicity. So far, this
pathway has been reported only at the in vitro level (Kim et al,
2006), or as a result of the administration of a single high
(supratherapeutic) dose of doxorubicin in vivo (Jang et al, 2004).
Our present findings agree well with the available data, as
profound ultrastructural and functional effects on ER/SR have
been reported after repeated administration of ANTs in vivo
(Minotti et al, 2004).
It is noteworthy that, in this study, we have observed that signs
of significant cell degeneration and nuclear TUNEL positivity were
only very rarely present in a single cardiomyocyte. Instead,
although both these processes evidently co-existed in the LV
myocardium as a whole, they typically affected different cardio-
myocytes. We failed to find any regular pattern of distribution of
cells with TUNEL-positive nuclei within the LV myocardium.
Generally, apoptosis seemed to have a less significant function
within the foci of the cardiomyocytes exhibiting advanced
degenerative changes. Although advanced degenerative changes
seemed to be more prominent in the animals with the most
profound cardiotoxicity, we cannot yet apportion the contribution
of each of these processes to heart failure induced by anthracy-
clines. At this point, it should be stressed that, although apoptosis
is completely finished within several hours, degenerative changes
evidently progress relatively slowly, which hinders an appropriate
head-to-head comparison of the real contribution of both
processes to the clinical manifestation of ANT cardiotoxicity.
Although there is solid evidence for induction of apoptosis after
the exposure of cardiac myocytes to ANTs, one of the important
questions has remained hitherto unanswered: Is modulation of
apoptotic cell death involved in the remarkably effective cardio-
protection afforded by DEX? Scanty data from the literature have
suggested that this might be true, at least at the level of the isolated
cardiomyocytes exposed acutely to ANTs (Sawyer et al, 1999).
Nevertheless, in this study, we showed for the first time that DEX is
able to significantly and nearly completely rescue cardiomyocytes
from ANT-induced apoptosis under clinically relevant chronic in
vivo conditions. Furthermore, the current investigation reveals
that DEX prevents the ANT-induced activation of all major
upstream (i.e., caspases 8-, 9- and 12 dependent) pathways.
Importantly, all the examined parameters of apoptosis showed a
significant and strong correlation with LV systolic function in
individual animals. Indeed, the ability of DEX to prevent the
triggering of multiple apoptotic pathways may account for its high
efficacy in the prevention of ANT-induced apoptotic cell death in
the LV myocardium. Further information regarding the relation-
ships between the apoptotic and other studied parameters was
obtained from two independent exploratory data analyses. These
revealed that DEX showed a clear tendency towards reduction of
both apoptotic and non-apoptotic cell death. It is noteworthy that
the activities of apoptotic caspases were determined to have the
strongest impact on the natural grouping of individual animals,
which highlights apoptosis as an extremely important target for
cardioprotective intervention with DEX. However, it should be
stated that we cannot draw any definitive conclusion regarding the
relative importance of these cardioprotective pathways at this
stage.
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Figure 9 (A) Horizontal Hierarchical Tree Plot. The analysis comprised LV functional parameters (FS and dP/dtmax), the plasma levels of cardiac troponins
T and I, markers of apoptosis (TUNEL positivity and activities of caspases) and lipoperoxidation (nine variables) in all experimental groups. The analysis
resulted in two main clusters. The first cluster covers exclusively the individuals from the control (C) and DEX co-treated group (DD), whereas the second
cluster contains only the animals from the daunorubicin group (D), where almost all animals appeared in one cluster. (B) Principal Component Analysis
(PCA) scatterplots. This analysis of the same variables also revealed two distinctly separated clusters comprising the DEXþDAU and control groups in the
first, with all animals from the DAU group in the second cluster. Treatment groups: control (n), DAU (m) and DEXþDAU (&).
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cardiac myocytes from programmed and non-programmed cell
death, the mechanisms responsible for these effects remain elusive.
So far, the cardioprotective effects of DEX have been mostly
attributed to its ring-opening hydrolysis product ADR-925
(Kwok and Richardson, 2000; Cvetkovic and Scott, 2005). This
compound has been shown to displace iron from ANT–iron
complexes, and hence it has been assumed to prevent redox
cycling and production of extremely toxic hydroxyl radicals
(Hasinoff et al, 1998). Nevertheless, using the same experimental
model, the degree of cardioprotection afforded by DEX in this
study was apparently much higher than that obtained previously
with much stronger and selective aroylhydrazone iron chelators
(Simunek et al, 2005b; Sterba et al, 2006, 2007). Furthermore,
deferiprone, a novel clinically used cell permeable iron chelator,
failed to afford any meaningful cardioprotection under identical
conditions (Popelova et al, 2008). Hence, these data imply that the
iron-chelating properties of a compound are not the main
determinants of its cardioprotective action.
The ANT-induced formation of ROS is believed to induce a
profound myocardial oxidative injury to most of the biomolecules
in the LV myocardium and to phospholipids in particular (Keizer
et al, 1990). Hence, we sought to determine whether DEX-afforded
cardioprotection involves the prevention of ROS-induced damage
as a common denominator by means of total MDA measurement
by HPLC in whole-tissue extract prepared from LV myocardium.
This analytical approach is free of the known drawbacks associated
with the older thiobarbituric acid-based methods (Janero, 1990;
Esterbauer et al, 1991; Pilz et al, 2000). Using this method, we have
found significantly increased levels of MDA in the LV myocardium
of DAU-treated animals, suggesting that oxidative damage was
associated with the treatment. Although these data are well in line
with literature and traditional concepts (Doroshow et al, 1980;
Sarvazyan, 1996; Zhou et al, 2001), the finding that DEX failed to
overcome ANT-induced lipoperoxidation was highly novel and
rather surprising. It is noteworthy that the analytical method used
herein has been previously shown to be capable of documenting a
reduction of lipoperoxidation provided by pharmacological
cardioprotection using iron-chelating agents (Simunek et al,
2007). Moreover, similar results were also obtained using
complementary immunohistochemical detection of 4-HNE as
another marker of lipoperoxidation. These observations strikingly
contrasted with the powerful cardioprotection afforded by DEX in
these animals. In addition, the MDA levels showed only a poor
agreement with caspase 3/7 activity, and no correlation with the
activities of the main caspases of both extrinsic and intrinsic
pathways (caspases 8 and 9) were found. Moreover, this marker of
lipoperoxidation showed no relationship with LV systolic function.
We cannot exclude, however, the fact that DEX-afforded protection
against free radical injury may be primarily compartmentalised in
origin, although the immunohistochemical analysis of 4-HNE did
not suggest so. One also could expect that the protection afforded
in any particular compartment should still be reflected in the total
MDA levels, if in fact it is so crucial to the fate of the whole cell.
Nevertheless, we did not observe any such trend in this study.
These findings strongly suggest that the excellent cardioprotection
obtained with DEX is not primarily dependent on the protection
from ANT-induced lipoperoxidation. On the other hand, we
cannot exclude that there is a compartment within the cell that
might have a key function in ROS-dependent cardiotoxicity and
DEX-afforded cardioprotection, although it does not have a
striking impact on overall lipoperoxidation.
Using isolated rat cardiomyocytes, we have previously shown
that the chelator, salicylaldehyde isonicotinoyl hydrazone (SIH),
affords significant, although only partial, protection from DAU-
induced cell death. However, this protective effect was not
accompanied by any reduction of lipoperoxidation (Simunek
et al, 2008). This finding contrasted with the results obtained with
the same compound on the model of hydrogen peroxide-induced
oxidative stress (Simunek et al, 2005a, 2007, 2008). In this latter
case, the SIH-afforded protection of cardiomyocytes was markedly
better and clearly oxidative stress dependent. Furthermore, in
another study, DEX failed to mitigate doxorubicin-induced
peroxidative damage to A549 human lung adenocarcinoma cells
(Kaiserova et al, 2006).
Although further studies primarily designed to clarify this point
deserve to be performed, at this stage, we come to the inevitable
conclusion that the function of DEX has less to do with its ROS-
reduction capability. This might provide us an explanation for the
failure of previous attempts to provide effective cardioprotection
against ANT cardiotoxicity using a whole range of antioxidants
(e.g., vitamin E, acetylcysteine or flavonoids) in chronic
experimental models (Van Vleet et al, 1980; Herman et al,
1985; Bruynzeel et al, 2007b) and randomised clinical trials
(Dresdale et al, 1982; Legha et al, 1982; Myers et al, 1983;
Bruynzeel et al, 2007a). From this point of view, our results further
support the recent call for revisiting the classical ‘ROS and iron
hypothesis’ of ANT cardiotoxicity and DEX cardioprotection
(Gianni et al, 2008).
Indeed, the data from this study raise new questions about the
actual mechanisms underlying the protective action of DEX against
ANT cardiotoxicity. First, it should be noted that, unlike the iron-
chelating compounds studied previously (Sterba et al, 2006, 2007;
Popelova et al, 2008), the putative active metabolite of DEX (ADR-
925) is far from being a selective iron chelator. Owing to this non-
selectivity, it is plausible that intracellular chelation of other
biologically important multivalent metal cations could participate
in cardioprotective effects of DEX. Importantly, ANTs have been
repeatedly shown to impair tightly regulated calcium homoeostasis
in cardiac cells (Minotti et al, 2004; Wallace, 2007). We have
previously shown that ANT-induced calcium overload can be
prevented by DEX co-treatment (Simunek et al, 2005c). Further-
more, the determination of caspase 12 activity in this study
suggested an involvement of ER/SR stress, which was preventable
by DEX administration. In addition, others have reported that
mitochondrial calcium overload and/or activation of calcium-
dependent proteases are part of the key molecular mechanisms
of ANT cardiotoxicity development (Solem et al, 1994;
Lim et al, 2004).
Besides the above-discussed hypotheses that consider DEX
solely as a prodrug of the metal-chelating agent ADR-925, some
novel suggestions point at the importance of a direct cardiopro-
tective involvement of DEX (Hasinoff and Herman, 2007; Lyu et al,
2007). The DEX is a known catalytic inhibitor of topoisomerase II
and this action has also been considered as being responsible for
its anticancer effects. The DEX binds directly to topoisomerase II
and thereby locks the enzyme in a stable and closed clamp
conformation around DNA (Roca et al, 1994). On the other hand,
ANTs are also known to be topoisomerase II poisons that act
through the stabilisation of topoisomerase II-DNA covalent
complexes, resulting in DNA strand breaks (Minotti et al, 2004).
It has been hypothesised that DEX, as a catalytic inhibitor, might
have protective effects against topoisomerase II-poisoning agents
(Lyu et al, 2007).
In addition, there are reports indicating that the beta isoform of
topoisomerase II is abundant in the post-mitotic myocardium
(Wang, 2002), including mitochondria that are prominently
targeted by ANT cardiotoxicity (Wallace, 2003, 2007). A recent
in vitro study conducted on a H9c2 rat cardiomyoblast cell line has
suggested that DEX-promoted inhibition of topoisomerase II b
may have a significant function in the cardioprotective action of
the drug (Lyu et al, 2007). Another recent report dealing with a
new DEX derivative (ICRF-161) has shown that, unlike iron-
chelating properties, topoisomerase II inhibition might be of
primary importance for effective cardioprotection under chronic
in vivo conditions (Martin et al, 2009).
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afforded cardioprotection against chronic ANT cardiotoxicity in
vivo is based not only on the rescue of cardiomyocytes from
degenerative changes and non-programmed cell death but also on
rescue from programmed cell suicide – apoptosis of the ventricular
myocytes. ANT-induced apoptotic signalling seems to be very
complex, but DEX was shown to block all the major apoptotic
pathways. Clarification of the mechanisms responsible for the
potent protective action of DEX against the apoptotic death of
cardiac myocytes merits further study. Nevertheless, protection of
cardiac myocytes does not seem to be primarily lipoperoxidation
dependent. These findings point out to apoptosis being a part of
the cardioprotective action of DEX, and further underline the need
for revisiting the traditional but potentially oversimplified ‘ROS
and iron hypothesis’ of ANT cardiotoxicity.
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